Daewoong and Indonesia’s Ministry of Health Discuss Collaboration for Mutual Growth Aligned with Local Production of Medical Devices
(Jakarta, February 14th 2025)
Daewoong, a leading global pharmaceutical group based in South Korea, announced on February 14th that it had conducted an official visit alongside the Indonesian Minister of Health, Budi Gunadi Sadikin, to discuss the collaboration direction based on the Ministry’s seven pillars of health transformation as a key collaborative partner.
Especially, the Minister of Health emphasized the increasing importance of domestic production of pharmaceuticals and medical devices, particularly in relation to TKDN (Domestic Component Level), and stressed the necessity of ensuring a robust domestic supply chain for the health and safety of Indonesian citizens. “We are particularly concerned about the urgent need for domestic production of critical medical devices. We hope that Daewoong will contribute to the local production of these medical devices in Indonesia,” the Minister added.
In response, Hyun Seung Yu, CEO of CGBIO, stated: “This collaboration marks a significant milestone in aligning CGBIO's global vision with Indonesia’s goal of achieving medical device self-reliance. Through continued research collaborations with Indonesian universities and the establishment of a local manufacturing facility, we aim to position Indonesia as a leading medical device hub in Asia.”
CGBIO, a specialized medical device production affiliate of Daewoong Group, has reaffirmed its commitment to establishing a medical device manufacturing plant in Indonesia. The company plans to utilize local resources for production and technology transfer, further strengthening Indonesia’s position in the medical device industry.
Eric Aoh, Head of the Business Team at CGBIO, also stated, “CGBIO is not only committed to producing medical products in Indonesia but also to enhancing the professionalism of doctors. That is why we continue to organize learning sessions for doctors, such as the VCP program and KOL conference.”
During the visit, Minister Budi Gunadi Sadikin also expressed his deep appreciation for Daewoong’s efforts in nurturing Indonesian talent to Daewoong Biologics Indonesia (led by Shawn Park) and its subsidiary CGBIO (led by CEO Hyun Seung Yu). The Minister was particularly impressed by the development of young talents in Indonesia, through Daewoong's initiatives which have been cultivating their expertise and transforming into global talents.
Since 2009, Daewoong has been a steadfast supporter of global talent development, awarding scholarships to over 2,000 outstanding students at top Indonesian universities. In addition, Daewoong has supported more than 100 medical professionals and facilitated technology transfer to bolster research in healthcare. A key highlight of Daewoong’s ongoing collaboration is its joint research with prominent Indonesian universities, such as UI, ITB, and IPB.
Minister Budi Gunadi Sadikin shared his experience: “When I visited Daewoong in 2021, I was deeply moved to witness Indonesian youth growing into global talents, thanks to Daewoong's commitment to fostering their skills through scholarships and technical support. These efforts not only enhance the capabilities of Indonesian individuals but also significantly contribute to improving the nation’s healthcare system and overall quality of life.”
Baik In Hyun, Head of Daewoong Biologics Indonesia’s business unit, expressed gratitude to the Ministry of Health: “We are thankful to the Ministry of Health of Indonesia, a strategic partner of Daewoong for over 20 years, for their unwavering support in fostering shared growth and elevating the healthcare quality and well-being of Indonesia. We remain fully committed to deepening our collaboration with Indonesia, empowering its top talents, and helping bring them to the global stage.”
Additionally, Daewoong has been a key player in Indonesia’s biopharmaceutical sector since the opening of its Jakarta branch in 2005. In 2012, Daewoong established Daewoong Infion, Indonesia’s first biopharmaceutical production facility, which supports technology transfer for biopharmaceutical manufacturing and offers Halal-certified EPO and EGF medicines. Further solidifying its commitment to local production, Daewoong completed the construction of a state-of-the-art stem cell therapy facility in Indonesia in 2024. This 20-year journey exemplifies Daewoong’s unwavering dedication to mutual growth and innovation in partnership with Indonesia.
Finally, Minister Budi Gunadi Sadikin underscored the need to strengthen the competencies of the Ministry of Health’s human resources, which aligns with the seventh pillar of Indonesia’s health transformation. In light of this, Daewoong expressed its confidence in supporting the Ministry’s initiatives through various collaborations, such as the invitation program with Indonesian Ministry of Health’s Internal Transformation Office held last September, where Daewoong shared its growth-centered key human resource programs and interacted with young Indonesian talents working at Daewoong.
# # #
